Vaccine delivery compositions and methods of use

A vaccine delivery composition comprising:

• an effective amount of at least one MHC class I or class II peptidic antigen conjugated to particles or molecules of a biodegradable poly(ester amide) (PEA) polymer having a chemical structure described by structural formula (I),
• wherein n ranges from about 5 to about 150;
• R1 is independently selected from residues of α,ω-bis(4-carboxyphenoxy)-(C1-C8)alkane, 3,3′-(alkanedioyldioxy)dicinnamic acid or 4,4′-(alkanedioyldioxy)dicinnamic acid, (C2-C20)alkylene, or (C2-C20)alkenylene;
• the R3s in individual n monomers are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl(C1-C20)alkyl, and —(CH2)2S(CH3);
• and R4 is independently selected from the group consisting of (C2-C20)alkylene, (C2-C20)alkenylene, (C2-C8)alkyloxy, (C2-C20)alkylene, a residue of a saturated or unsaturated therapeutic diol, bicyclic-fragments of 1,4:3,6-dianhydrohexitols of structural formula (II), and combinations thereof, (C2-C20)alkylene, and (C2-C20)alkenylene;
• or a PEA polymer having a chemical formula described by structural formula (III):
• wherein n ranges from about 5 to about 150, m ranges about 0.1 to 0.9:
• p ranges from about 0.9 to 0.1;
• wherein R1 is independently selected from residues of α,ω-bis(4-carboxyphenoxy)-(C1-C8)alkane, 3,3′-(alkanedioyldioxy)dicinnamic acid or 4,4′-(alkanedioyldioxy)dicinnamic acid, (C2-C20)alkylene, or (C2-C20)alkenylene;
• each R2 is independently hydrogen, (C1-C12)alkyl or (C6-C10)aryl or a protecting group;
• the R3s in individual m monomers are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl(C1-C20)alkyl, and —(CH2)2S(CH3);
• and R4 is independently selected from the group consisting of (C2-C20)alkylene, (C2-C20)alkenylene, (C2-C8)alkyloxy, (C2-C20)alkylene, a residue of a saturated or unsaturated therapeutic diol or bicyclic-fragments of 1,4:3,6-dianhydrohexitols of structural formula (II), and combinations thereof
• or a poly(ester urethane) (PEUR) polymer having a chemical formula described by structural formula (IV),
• wherein n ranges from about 5 to about 150;
• wherein R3s in independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl(C1-C20)alkyl, and —(CH2)2S(CH3);
• R4 is selected from the group consisting of (C2-C20)alkylene, (C2-C20)alkenylene or alkyloxy, a residue of a saturated or unsaturated therapeutic diol, bicyclic-fragments of 1,4:3,6-dianhydrohexitols of structural formula (II);
• and combinations thereof, and R6 is independently selected from (C2-C20)alkylene, (C2-C20)alkenylene or alkyloxy, bicyclic-fragments of 1,4:3,6-dianhydrohexitols of general formula (II), and combinations thereof;
• or a PEUR polymer having a chemical structure described by general structural formula (V)
• wherein n ranges from about 5 to about 150, m ranges about 0.1 to about 0.9:
• p ranges from about 0.9 to about 0.1;
• R2 is independently selected from hydrogen, (C6-C10)aryl(C1-C20)alkyl, or a protecting group;
• the R3s in an individual m monomer are independently selected from the group consisting of hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl(C1-C20)alkyl and —(CH2)2S(CH3);
• R4 is selected from the group consisting of (C2-C20)alkylene, (C2-C20)alkenylene or alkyloxy, a residue of a saturated or unsaturated therapeutic diol and bicyclic-fragments of 1,4:3,6-dianhydrohexitols of structural formula (II) and combinations thereof;
• and R6 is independently selected from (C2-C20)alkylene, (C2-C20)alkenylene or alkyloxy, bicyclic-fragments of 1,4:3,6-dianhydrohexitols of general formula (II), an effective amount of a residue of a saturated or unsaturated therapeutic diol, and combinations thereof;
• or a poly(ester urea) (PEU) having a chemical formula described by general structural formula (VI):
• wherein n is about 10 to about 150;
• the R3s within an individual n monomer are independently selected from hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl(C1-C20)alkyl and —(CH2)2S(CH3);
• R4 is independently selected from (C2-C20)alkylene, (C2-C20)alkenylene, (C2-C8)alkyloxy(C2-C20)alkylene, a residue of a saturated or unsaturated therapeutic diol;
• or a bicyclic-fragment of a 1,4:3,6-dianhydrohexitol of structural formula (II);
• or a PEU having a chemical formula described by structural formula (VII)
• wherein m is about 0.1 to about 1.0;
• p is about 0.9 to about 0.1;
• n is about 10 to about 150;
• each R2 is independently hydrogen, (C1-C12)alkyl or (C6-C10)aryl;
• the R3s within an individual m monomer are independently selected from hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl(C1-C20)alkyl and —(CH2)2S(CH3);
• each R4 is independently selected from (C2-C20)alkylene, (C2-C20)alkenylene, (C2-C8)alkyloxy(C2-C20)alkylene, a residue of a saturated or unsaturated therapeutic diol;
• a bicyclic-fragment of a 1,4:3,6-dianhydrohexitol of structural formula (II), and combinations thereof.
• or (III).